Related Experiment Video
Updated: May 16, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Monoclonal antibodies in lung cancer
Yujiong Wang1, Guangcun Deng, Xiaoming Liu
1Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China, Yinchuan, Ningxia, China.
Introduction:
Lung cancer is the leading cause of cancer death worldwide. As clinical benefits to conventional cancer therapies are still formidable, there is an urgent need for novel agents and approaches to improve the overall clinical outcomes for patients with lung cancer.
Areas Covered:
This article reviews the current understanding of targeted therapy for lung cancer with monoclonal antibodies (mAbs), mainly bevacizumab and cetuximab. The results from several key clinical trials validating the effectiveness and safety of bevacizumab and cetuximab, the relation of cancer biomarkers, the polymorphic correlation of targeted genes with the therapeutic outcome of mAb-based treatment, as well as the impact of Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial on personalised treatment of lung cancer are discussed.
Expert Opinion:
The addition of bevacizumab or cetuximab to chemotherapy has shown promising benefits to the patients with non-small-cell lung cancer. However, the overall benefits of mAb-based targeted therapy to lung cancer patients vary among individuals. It is therefore necessary to define reliable predictive biomarkers in an effort to better identify patients who are most likely to benefit from treatment with these novel agents in lung cancer.
Insights
Monoclonal antibodies like bevacizumab and cetuximab show promise in lung cancer treatment. Identifying predictive biomarkers is crucial for personalizing therapy and improving patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lung cancer remains a leading global cause of cancer mortality.
- Conventional therapies present significant challenges, necessitating novel treatment strategies.
Purpose of the Study:
- To review targeted therapy for lung cancer using monoclonal antibodies (mAbs).
- To discuss the role of biomarkers and personalized medicine in mAb treatment.
Main Methods:
- Review of key clinical trials on bevacizumab and cetuximab efficacy and safety.
- Analysis of cancer biomarkers and gene polymorphisms in relation to mAb treatment outcomes.
- Discussion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.
Main Results:
- Bevacizumab and cetuximab, when added to chemotherapy, demonstrate benefits for non-small-cell lung cancer patients.
- Individual patient responses to mAb-based targeted therapy for lung cancer vary significantly.
Conclusions:
- Monoclonal antibody therapy offers promising outcomes for lung cancer patients.
- Reliable predictive biomarkers are essential to identify patients most likely to benefit from bevacizumab and cetuximab.
- Personalized treatment approaches are key to optimizing lung cancer therapy.
